Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Peter E LonerganEmily A VertosickMelissa AsselDaniel D SjobergAlexander HaeseMarkus GraefenStephen A BoorjianGeorge G KleeMatthew R CooperbergKim PetterssonErica RoutilaAndrew Julian VickersHans G LiljaPublished in: BJU international (2020)
A prospective multicentre evaluation of a pre-specified model based on four kallikrein markers (4Kscore) with the addition of MSP improves the predictive discrimination for GG ≥2 prostate cancer on biopsy and could be used to inform biopsy decision-making.